Data about the circulating levels of cyclophilin A and matrix metalloproteinase-9 in stable coronary artery disease are contradictory. Moreover, their relationship in this disease is not established yet. Thus, this study was designed to assess the relationship between the circulating levels of cyclophilin A and matrix metalloproteinase-9 in coronary artery disease patients with and without type 2 diabetes mellitus (T2DM).
Methods
Serum levels of cyclophilin A, matrix metalloproteinase-9, and high sensitive C-reactive protein (hsCRP) along with fasting blood glucose, glycated hemoglobin, serum lipids, and the anthropometric parameters were measured in 120 participants who were divided equally into four groups (i) normal controls, (ii) T2DM patients, (iii) stable coronary artery disease patients with T2DM, and (iv) stable coronary artery disease patients without T2DM.
Results
Levels of cyclophilin A and matrix metalloproteinase-9 were significantly elevated in sera of coronary artery disease patients with and without T2DM compared to normal controls and T2DM patients. In multiple linear regression models, only cyclophilin A was observed in the final model where it explained the 24.9% variability of matrix metalloproteinase-9. Additionally, high circulating levels of cyclophilin A and matrix metalloproteinase-9 were associated with an increased risk of developing stable coronary artery disease. Finally, the diagnostic efficacy of cyclophilin A and matrix metalloproteinase-9 to discriminate stable coronary artery disease patients with and without T2DM from subjects without coronary artery disease was found to be higher than that of hsCRP.
Conclusion
Serum level of cyclophilin A might be a determinant factor of matrix metalloproteinase-9 level; both may contribute to the pathogenesis of stable coronary artery disease and they appear to be valuable diagnostic biomarkers of stable coronary artery disease with and without T2DM.
GBD 2013 Mortality and Causes of Death Collaborators.
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet2015;
385: 117–171.
2.
LaaksoM.Cardiovascular disease in type 2 diabetes from population to man to mechanisms. Diabetes Care2010;
33: 442–449.
3.
PreisSRPencinaMJHwangSJ, et al.
Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation2009;
120: 212–220.
4.
HammoudTTanguayJFBourassaMG.Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol2000;
36: 355–365.
5.
SatohKShimokawaHBerkBC.Cyclophilin A: promising new target in cardiovascular therapy. Circ J2010;
74: 2249–2256.
6.
AroraKGwinnWMBowerMA, et al.
Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol2005;
175: 517–522.
7.
SuzukiJJinZGMeoliDF, et al.
Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res2006;
98: 811–817.
8.
SatohKFukumotoYShimokawaH.Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol2011;
301: H287–H296.
9.
SatohK.Cyclophilin A in cardiovascular homeostasis and diseases. Tohoku J Exp Med2015;
235: 1–15.
10.
SatohKFukumotoYSugimuraK, et al.
Plasma cyclophilin A is a novel biomarker for coronary artery disease. Circ J2013;
77: 447–455.
11.
RamachandranSVenugopalAKuttyVR, et al.
Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease. Cardiovasc Diabetol2014;
13: 38.
12.
SternlichtMDWerbZ.How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol2001;
17: 463–516.
13.
WelshPWhincupPHPapacostaO, et al.
Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM2008;
101: 785–791.
14.
MuzzioMLMiksztowiczVBritesF, et al.
Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res2009;
40: 48–53.
15.
DoganATuzunNTurkerY, et al.
Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia. Coron Artery Dis2008;
19: 559–563.
16.
BlankenbergSRupprechtHJPoirierO, et al.
Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation2003;
107: 1579–1585.
17.
TomitaTNakaseTKanekoM, et al.
Expression of extracellular matrix metalloproteinase inducer and enhancement of the production of matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum2002;
46: 373–378.
18.
LaiWCZhouMShankavaramU, et al.
Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J Immunol2003;
170: 6244–6449.
19.
YurchenkoVZybarthGO’ConnorM, et al.
Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem2002;
277: 22959–22965.
20.
PushkarskyTYurchenkoVVanpouilleC, et al.
Cell surface expression of CD147/EMMPRIN is regulated by cyclophilin 60. J Biol Chem2005;
280: 27866–27871.
21.
SeizerPSchönbergerTSchöttM, et al.
EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis2010;
209: 51–57.
22.
FriedewaldWTLevyRIFredricksonDS.Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem1972;
18: 499–502.
23.
JinZGMelaragnoMGLiaoDF, et al.
Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res2000;
87: 789–796.
24.
JinZGLunguAOXieL, et al.
Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol2004;
24: 1186–1191.
25.
KhromykhLMKulikovaNLAnfalovaTV, et al.
Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell Immunol2007;
249: 46–53.
GalisZSMuszynskiMSukhovaGK, et al.
Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res1994;
75: 181–189.
28.
IkedaUTakahashiMShimadaK.Monocyte-endothelial cell interaction in atherogenesis and thrombosis. Clin Cardiol1998;
21: 11–14.
29.
YanJZangXChenR, et al.
The clinical implications of increased cyclophilin A levels in patients with acute coronary syndromes. Clin Chim Acta2012;
413: 691–695.
30.
BaasASBerkBC.Differential activation of mitogen-activated protein kinases by H2O2 and O2− in vascular smooth muscle cells. Circ Res1995;
77: 29–36.
31.
AlexanderRW.Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension1995;
25: 155–161.
32.
SatohKFukumotoYNakanoM, et al.
Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res2009;
81: 226–234.
33.
ZengBPrasanAFungKC, et al.
Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J2005;
35: 331–335.
34.
HamedGMFattahMF.Clinical relevance of matrix metalloproteinase 9 in patients with acute coronary syndrome. Clin Appl Thromb Hemost2015;
21: 705–711.
35.
JönssonSLundbergAKälvegrenH, et al.
Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris. PLoS One2011;
6: e19340.
36.
WangCHDaiJYWangL, et al.
Expression of CD147 (EMMPRIN) on neutrophils in rheumatoid arthritis enhances chemotaxis, matrix metalloproteinase production and invasiveness of synoviocytes. J Cell Mol Med2011;
15: 850–860.
37.
NigroPSatohKO’DellMR, et al.
Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med2011;
208: 53–66.
38.
KimSHLessnerSMSakuraiY, et al.
Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am J Pathol2004;
164: 1567–1574.
39.
YuanWGeHHeB.Pro-inflammatory activities induced by CyPA-EMMPRIN interaction in monocytes. Atherosclerosis2010;
213: 415–421.
40.
ZhuDWangZZhaoJJ, et al.
The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med2015;
21: 572–580.
41.
ZhangMDaiCZhuH, et al.
Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9. Mol Cell Biochem2011;
357: 387–395.
42.
QianZZhaoXJiangM, et al.
Downregulation of cyclophilin A by siRNA diminishes non-small cell lung cancer cell growth and metastasis via the regulation of matrix metallopeptidase 9. BMC Cancer2012;
12: 442.
43.
YangYLuNZhouJ, et al.
Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford)2008;
47: 1299–1310.
44.
Task Force MembersMontalescotGSechtemU, et al.
ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J2013;
34: 2949–3003.
45.
FilipovicNRosicMTanaskovicI, et al.
Computer simulation and experimental analysis of LDL transport in the arteries. Conf Proc IEEE Eng Med Biol Soc2011;
2011: 195–198.
46.
Tian-TianZJun-FengZHengG.Functions of cyclophilin A in atherosclerosis. Exp Clin Cardiol2013;
18: e118–e124.
47.
BellRDWinklerEASinghI, et al.
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature2012;
485: 512–516.
48.
LallaELamsterIBHofmannMA, et al.
Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol2003;
23: 1405–1411.
49.
SoderPOMeurmanJHJogestrandT, et al.
Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in blood as markers for early atherosclerosis in subjects with chronic periodontitis. J Periodontal Res2009;
44: 452–458.
50.
GalisZSJohnsonCGodinD, et al.
Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res2002;
91: 852–859.
51.
SeizerPGeislerTBigalkeB, et al.
EMMPRIN and its ligand Cyclophilin A as novel diagnostic markers in inflammatory cardiomyopathy. Int J Cardiol2013;
163: 299–304.
52.
LahdentaustaLLeskeläJWinkelmannA, et al.
Serum MMP-9 diagnostics, prognostics, and activation in acute coronary syndrome and its recurrence. J Cardiovasc Trans Res2018;
11: 210–220.
